IMMUNOTHERAPY FOR ALZHEIMERS: EXCITING NEW CLINICAL TRIAL- Raymond Rupert MD, MBA. Rupert Case Management Inc.
U of T neurology professor Sandra Black is cautiously optimistic around positive results of a new Alzheimer’s drug reported last week in the high impact journal Nature. “It’s close to being very promising and potentially very exciting,” Black, a senior scientist at Sunnybrook Health Sciences Centre, told the Toronto Star, noting that Sunnybrook is a clinic site for […] Read More
The 311 medicines in development for patients with autoimmune diseases use exciting new approaches aided by the growing scientific understanding of many of these diseases. In addition, medicines already approved to treat one autoimmune disease are being studied for applicability in treating additional diseases. Some of the medicines in the pipeline for autoimmune diseases […] Read More
Something for patients and oncologists to consider in their future treatment plans. Vaxil Biotherapeutics has developed and is testing a cancer vaccine. Immucin is the vaccine. The vaccine is very innovative. It attacks the MUC1 marker on the tumour cell. About 90% of tumours have MUC1 markers. By attacking this marker, it makes the tumour […] Read More
Sometimes you have to get to the brain by using the body. Joaquin Farias has spent the past two decades trying to understand dystonia, a confounding and sometimes debilitating syndrome believed to be the third-most-common neurological movement disorder, after essential tremor and Parkinson’s disease. His work has been influenced by his own experience. As […] Read More
Against the ruin of the world, there is only one defense — the creative act. Disengagement: The Art Of The Beat Generation, Kenneth Rexroth 1957 Most don’t consider creativity important or essential in treating complex patients. But this decisive act is the true measure of providing value for these patients. It is easy to slip […] Read More